Eli Lilly and Co
A read-only Alphactor snapshot for Eli Lilly and Co. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of 2026-04-17
Topline snapshot
Latest Close
$927.03
30-Day Move
-6.7%
Market Cap
$884.0B
Shares Outstanding
943,360,000
P/E Ratio
42.83
P/B Ratio
38.29
$927.03
-6.7%last 90 delayed daily bars
90D High
$1133.95
90D Low
$877.11
Avg Volume
3,086,017
Gross margin is running at 83.0%, which gives a quick read on operating quality before you open the full model.
Net margin is 31.7%, useful for comparing LLY against peers in Pharmaceuticals.
LLY is down 6.7% over the last 30 trading days shown on this page.
Latest operating income is $29.7B, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$67.28
Rule of 40
-9.1%
Latest Close
$927.03
30-Day Move
-6.7%
Market Cap
$884.0B
Shares Outstanding
943,360,000
P/E Ratio
42.83
P/B Ratio
38.29
ROE
77.8%
ROA
18.4%
Gross Margin
83.0%
Operating Margin
40.4%
Net Margin
31.7%
Debt / Equity
1.6
Current Ratio
1.58
Dividend Yield
78.8%
Latest Revenue
$65.2B
Revenue
$65.2B
Gross Profit
$54.1B
Operating Income
$29.7B
Net Income
$20.6B
Gross Margin
8304.0%
Net Margin
3166.0%
Current Ratio
1.58
Debt / Equity
1.60
Fair Value
$67.28
Upside / Downside
-92.7%
Signal
Overvalued
Implied Growth
34.5%
DCF
$71.08
EPV
$24.62
EV/Rev
$106.13
Growth Assumption
1.7%
Discount Rate
8.2%
Terminal Growth
2.0%
Base FCF
$4.8B
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
15.74
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
0.58x
Rule of 40
-9.1%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2016-12-31 | $21.2B | $3.4B | $2.7B | -- |
| 2017-12-31 | $22.9B | $2.2B | $-204M | -- |
| 2018-12-31 | $24.6B | $3.8B | $3.2B | -- |
| 2019-12-31 | $22.3B | $5.3B | $8.3B | -- |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Coatue Management
Filed 2025-11-14
--
--
Lone Pine Capital
Filed 2025-08-14
--
--
Vanguard Group
Filed 2026-01-29
$88.1B
+1.2%
BlackRock
Filed 2024-08-13
$59.6B
--
FMR LLC (Fidelity)
Filed 2026-02-17
$27.6B
+6.4%
Capital Research Global Investors
Filed 2026-02-11
$26.4B
-2.1%
Geode Capital Management
Filed 2026-02-09
$21.2B
-0.0%
4.05
Consensus
Buy—
—
—
39
For informational and educational purposes only. Not financial advice. Learn more